Clinical Trial

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2016-08-12; most recent amendment 2018-03-08.
Trial Details
NCT Number NCT02870244
Lead Sponsor Loyola University
Collaborators: National Cancer Institute (NCI)
Conditions Melanoma
Enrollment 18 participants
Start Date 2015-02
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2018-03-12